Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Aug 31, 2026
Cardiol Therapeutics (CRDL) +69% Rally in 30 Days: Pipeline Momentum Builds

Cardiol Therapeutics (CRDL) +69% Rally in 30 Days: Pipeline Momentum Builds

Key Takeaways

  • CRDL shares rose roughly 69% over the past 30 days, climbing from $1.15 to $1.94.
  • The advance was driven by a better-than-expected second-quarter earnings report and a series of bullish analyst actions.
  • Cardiol Therapeutics is a pre-revenue, clinical-stage biotech advancing CardiolRx, its oral cannabidiol candidate, through a pivotal Phase 3 trial in recurrent pericarditis.
  • Analyst price targets remain well above the current share price, though clinical, regulatory, and financing risks persist.

Company Overview and Market Position

Cardiol Therapeutics Inc. (CRDL) is a clinical-stage life sciences company headquartered in Oakville, Canada, focused on developing anti-inflammatory and anti-fibrotic therapies for heart disease. Its lead candidate, CardiolRx, is a pharmaceutically manufactured oral formulation of cannabidiol (CBD). The company is evaluating CardiolRx in the MAVERIC program, which includes a completed Phase 2 pilot study and an ongoing pivotal Phase 3 trial in recurrent pericarditis, a painful inflammatory condition of the sac surrounding the heart. The U.S. Food and Drug Administration has granted orphan drug designation to CardiolRx for the treatment of pericarditis. Cardiol also previously completed the Phase 2 ARCHER study of CardiolRx in acute myocarditis and is developing CRD-38, a subcutaneous formulation targeting heart failure. I also checked this using Tickeron’s AI Trend Prediction Engine to get a quick read on sector momentum.

Stock Price Performance: Last 30 Days vs. Quarter

Over the last 30 days, CRDL has delivered a sharp rally. The stock closed at $1.15 on July 29, 2026, and climbed to $1.94 by August 28, 2026, representing a gain of approximately 69%. The move was punctuated by a pronounced single-session jump in mid-August following the company's quarterly results. The broader trend has been similarly constructive: shares opened July near $1.05 and have advanced more than 80% since, extending a recovery from the stock's 52-week low of $0.88. The gains have been accompanied by meaningfully higher trading volume on several sessions, reflecting increased investor attention on the clinical-stage story. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

What Drove the Stock Price in the Last 30 Days

The primary catalyst was the company's second-quarter 2026 earnings release on August 12, 2026. Cardiol reported a narrower-than-expected loss, with earnings per share of approximately -$0.036 versus a consensus estimate of -$0.07, and the stock advanced about 12.5% in the following session. Investor confidence was further supported by analyst activity. Canaccord Genuity raised its price target on the stock to $10.00 in mid-August, while H.C. Wainwright maintained a Buy rating with a $9.00 target and Brookline Capital Markets holds a Buy rating with a $6.00 target. The company's participation in the Canaccord Genuity Growth Conference in Boston also boosted visibility. These developments, combined with progress updates on the MAVERIC Phase 3 program, helped sustain the upward momentum through the final weeks of August.

What Drove Stock Performance Over the Last Quarter

The quarterly advance reflects a broader re-rating of Cardiol's clinical pipeline rather than a single event. Over the trailing quarter, investor attention has focused on the progression of the MAVERIC Phase 3 trial in recurrent pericarditis and the company's differentiated position in cardiovascular inflammation. Cardiol's lean cost structure, minimal debt, and reported improvement in cash burn relative to prior periods have reinforced the view that management has flexibility to sequence clinical spending. The stock's recovery from its 52-week low also coincided with renewed sell-side coverage and firm price targets well above prevailing market levels, suggesting analysts anticipate significant potential value tied to upcoming clinical milestones.

Stock Forecast Drivers: What Investors Should Watch Next

Looking ahead, the most important catalyst for CRDL is the outcome of the MAVERIC Phase 3 trial in recurrent pericarditis, along with any regulatory updates tied to the FDA orphan drug designation. Investors should also monitor the company's cash position and financing activity, given its pre-revenue status and ongoing research and development spending. Analyst expectations remain a key sentiment driver, particularly whether additional firms initiate or revise coverage. Broader sector factors, including investor appetite for clinical-stage cardiovascular and specialty therapeutics, will also influence near-term price action. As with any development-stage biotech, clinical, regulatory, and capital-raising risks remain material considerations.

Using AI Tools in My Research Process

In my own work, I turn to Tickeron’s Trending AI Robots to see how automated systems are handling similar clinical-stage names. The page highlights top-performing bots from a broad universe, letting me compare strategies and timeframes without relying on any single approach. It gives a useful data-driven perspective that complements traditional analysis when I am evaluating names like CRDL.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: CRDL

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


CRDL's RSI Indicator peaks and leaves overbought zone

The 10-day RSI Oscillator for CRDL moved out of overbought territory on September 10, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 36 instances where the indicator moved out of the overbought zone. In 33 of the 36 cases the stock moved lower in the days that followed. This puts the odds of a move down at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on September 15, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CRDL as a result. In 83 of 99 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 84%.

The Moving Average Convergence Divergence Histogram (MACD) for CRDL turned negative on September 10, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In 43 of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at 88%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CRDL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +3.86% 3-day Advance, the price is estimated to grow further. Considering data from situations where CRDL advanced for three days, in 177 of 220 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.

The Aroon Indicator entered an Uptrend today. In 116 of 134 cases where CRDL Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 87%.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. CRDL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (13.263) is normal, around the industry mean (43.618). P/E Ratio (0.000) is within average values for comparable stocks, (141.316). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.181). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (178.797).

The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CRDL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 82, placing this stock worse than average.

Notable companies

The most notable companies in this group are Teva Pharmaceutical Industries Limited (NYSE:TEVA), ZOETIS (NYSE:ZTS), Elanco Animal Health (NYSE:ELAN), BioCryst Pharmaceuticals (NASDAQ:BCRX), Bausch Health Companies (NYSE:BHC), Tilray Brands Inc. (NASDAQ:TLRY), Canopy Growth Corp (NASDAQ:CGC), Aurora Cannabis (NASDAQ:ACB), Journey Medical Corp (NASDAQ:DERM).

Industry description

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

Market Cap

The average market capitalization across the Pharmaceuticals: Generic Industry is 4.11B. The market cap for tickers in the group ranges from 2.12K to 64.79B. MKKGY holds the highest valuation in this group at 64.79B. The lowest valued company is CANQF at 2.12K.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Generic Industry was 6%. For the same Industry, the average monthly price growth was -5%, and the average quarterly price growth was 42%. IMCC experienced the highest price growth at 79%, while APUS experienced the biggest fall at -20%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Generic Industry was 31%. For the same stocks of the Industry, the average monthly volume growth was 31% and the average quarterly volume growth was 5%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 52
P/E Growth Rating: 63
Price Growth Rating: 56
SMR Rating: 87
Profit Risk Rating: 82
Seasonality Score: -11 (-100 ... +100)
View a ticker or compare two or three
CRDL
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Industry PharmaceuticalsGeneric

Profile
Details
Industry
N/A
Address
2265 Upper Middle Road East
Phone
+1 289 910-0850
Employees
23
Web
https://www.cardiolrx.com
Interact to see
Advertisement
Elite Returns in a Volatile Sector — Both robots delivered annualized returns above 94%, outperforming the vast majority of active semiconductor funds. High Consistency — Win rates of 68–71% mean these robots win more often than they lose — a rare edge in a sector famous for violent swings.
Exceptional Returns: +79.13% annualized return on a starting balance of $8,040.74, demonstrating consistent alpha generation in the comms-tech sector. High Win Rate: 59.43% of trades close in profit, with a Profit Factor of 2.65 — meaning every $1 risked historically returns $2.65.
Tight Risk Management — The 3% TP / 2% SL corridor keeps risk-reward structured and disciplined, cutting losses quickly while locking in gains before reversals. Right Tickers, Right Time — XOM, CVX, and COP are all up roughly 30% year-to-date in 2026, making them among the most high-momentum, liquid energy plays in the market right now.
AngloGold Ashanti (AU) shares are tumbling approximately 11% in premarket trading on March 19, 2026, extending a steep multi-week correction that has now erased more than 35% of the stock's value from its March 2 peak of $129.14. The primary sustained catalyst driving the decline is AngloGold's lowered 2026 production guidance, projecting gold output of 2.80–3.17 million ounces — a mid-point decline versus the company's 2025 output of approximately 3.1 million ounces, and below analyst expectations.
CSIQ shares tumbled approximately 18% in premarket trading on March 19, 2026, following the release of deeply disappointing Q4 2025 earnings before the open. The company reported a net loss of $1.66 per diluted share, far worse than the Wall Street consensus estimate of -$0.98, representing a 69% earnings miss.
YRD shares are tumbling approximately 17% in premarket trading on March 19, 2026, from a prior close of $3.68 to approximately $3.05, following the company's release of Q4 and full-year 2025 financial results before the U.S. market open. Primary catalyst: A dramatic swing to net loss in Q4 2025. Yiren Digital reported a Q4 net loss of RMB 882.2 million (~USD 126.1 million), compared to net income of RMB 331.4 million in Q4 2024 — a more than $250 million deterioration year-over-year.
Shares of MU are down approximately 6.66% in premarket trading on March 19, 2026, sliding from a prior close of $461.73 to around $431.00. Despite a historic earnings beat — fiscal Q2 2026 revenue of $23.86 billion versus the $19.19 billion consensus, and adjusted EPS of $12.20 against an $8.79 estimate — the stock is experiencing a classic "sell the news" reaction.
NEM is trading approximately 9% lower in Thursday premarket, extending Wednesday's 4.56% session loss, as gold prices collapse following the Federal Reserve's hawkish policy hold. Gold spot prices fell 4.21% to $4,616.42 per ounce on March 19, marking the precious metal's sixth straight session of declines — its longest losing streak since late 2024.
Shares of VG are surging approximately +8% in Thursday's premarket session on March 19, 2026, with the stock trading near $16.04, up from the March 18 closing price of $14.85. The primary catalyst is a continuation of bullish momentum driven by a series of analyst price target upgrades, with Scotiabank most recently raising its target from $9 to $11.
LINC shares surged approximately +16% in premarket trading on March 19, 2026, reaching roughly $45.83 from a prior close of $39.51. Primary catalyst: Lincoln Educational Services is hosting its highly anticipated Investor Day today at its brand-new Nashville, TN campus, with presentations beginning at 10:00 am CT (11:00 am ET), live-streamed to investors globally.
PSLV is trading approximately 12% lower in premarket on March 19, 2026, tracking a violent selloff in silver futures. The Federal Reserve's hawkish hold on March 18 — keeping rates at 3.50%–3.75% while signaling fewer cuts ahead — was the primary macro trigger.
The Fed kept rates at 3.5–3.75% and signaled a “higher for longer” stance, with no urgency to cut and a willingness to tighten again if inflation stalls. This backdrop tends to favor quality growth, financials, energy, industrials, and health care, while pressuring long‑duration, leveraged sectors like speculative tech, small caps, utilities, and REITs.
PICS shares fell over 20% today, reversing much of their post‑IPO bounce and dropping well below the US$19 IPO price after initially trading in the mid‑US$15–16 range. The selloff followed PicPay’s Q4 and full‑year 2025 results, which showed strong revenue growth but highlighted thin margins, intense competition and ongoing execution risk in credit underwriting and payments.
RCAT shares fell over 16% today, dropping from recent levels near US$17 toward the mid‑US$14–15 range, after trading as high as US$18.78 in the past year and more than tripling from a 52‑week low of US$4.60.
HYMC shares fell over 13% today, sliding from the mid‑US$30s toward roughly US$31, after trading between US$2.30 and US$58.73 over the past 12 months and closing near US$39 just a few sessions ago.
USAS fell over 10% today, trading around US$5.83 by early afternoon from a previous close of US$6.55 — a one‑day decline of roughly 11% — as more than 5.9 million shares changed hands. The stock had surged earlier in 2026, with some data showing a move from about US$1.11 in March 2025 to over US$7.30 in mid‑March 2026 — a gain of more than 500% — leaving it vulnerable to profit‑taking.
CENX fell about 8.9% today, dropping US$4.94 to US$50.40 by midday, after closing at US$55.34 yesterday; shares now sit roughly 15% below their 52‑week high of US$59.12 but remain far above the 12‑month low of US$13.05. Q4 2025 results showed net sales of US$633.7 million and adjusted net income of US$128.2 million (US$1.25 per share), with adjusted EBITDA of US$170.6 million — a big sequential improvement — but GAAP net income was just US$1.8 million (US$0.02 per share), underscoring earnings volatility.
CNL shares fell over 8% today, trading down from around C$22.90 toward the low‑C$21s, after recently setting a new 1‑year high at C$28.99 on March 2 and gaining more than 70% over the past 12 months.
SMCI shares are plunging approximately 26% in Friday premarket trading, extending sharp after-hours losses from Thursday's session close of $30.79. The primary catalyst is a federal indictment unsealed March 19, 2026, charging three individuals associated with Super Micro — including a company co-founder — with conspiring to illegally export billions of dollars in AI server technology to China.
PL shares are surging approximately 19% in premarket trading on March 20, 2026, building on an 8.67% gain during the regular session on March 19. The primary catalyst is a blowout Q4 fiscal year 2026 earnings report released after the close on March 19, with quarterly revenue of $86.8 million — an 11.55% beat against consensus expectations of $77.81 million.
Cardiol Therapeutics (CRDL) +69% Rally in 30 Days: Pipeline Momentum Builds